epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLCepilepsia-5Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИБЕЗОПАСНОСТЬ И ПЕРЕНОСИМОСТЬ ЭСЛИКАРБАЗЕПИНА АЦЕТАТАЖидковаИ. А.

Жидкова Ирина Александровна  ― доктор медицинских наук, профессор кафедры нервных болезней лечебного факультета  ГБОУ ВПО «Московский государственный медико-стоматологический университет им А.И. Евдокимова» Минздрава России, невролог-эпилептолог медицинского центра «Невромед-клиника», член экспертного совета Российской Противоэпилептической Лиги

Московский государственный медико-стоматологический университет им А. И. Евдокимова, Москва; Невромед-клиника, МоскваRussian Federation20152905201670Special issue1112Copyright © Жидкова И.А., 20162016Жидкова И.А.Жидкова И.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/5

.

ReferencesИнструкция по медицинскому применению препарата Эксалиеф.Инструкция по медицинскому применению препарата Эксалиеф.Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S.D., Perucca E., Engel J. Jr., eds. The Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009:485-98.Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S.D., Perucca E., Engel J. Jr., eds. The Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009:485-98.Ben-Menachem E., Gabbai A.A., Hufnager A. et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010; 89: 278-85.Ben-Menachem E., Gabbai A.A., Hufnager A. et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010; 89: 278-85.Bialer M., Soares-da-Silva P. Pharmaco-kinetics and drug interactions of Eslicarbazepine acetate. Epilepsia. 2012; 53: 935-46.Bialer M., Soares-da-Silva P. Pharmaco-kinetics and drug interactions of Eslicarbazepine acetate. Epilepsia. 2012; 53: 935-46.Elger C., Halász P., Maia J. et al. Efficacy and safety of Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebocontrolled, parallel-group phase III study. Epilepsia. 2009; 50: 454-63.Elger C., Halász P., Maia J. et al. Efficacy and safety of Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebocontrolled, parallel-group phase III study. Epilepsia. 2009; 50: 454-63.Gil-Nagel A., Elger C., Ben-Menachem E. et al. Efficacy and safety of Eslicarbazepine acetate as add-on treatment in patients with focalonset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98-107.Gil-Nagel A., Elger C., Ben-Menachem E. et al. Efficacy and safety of Eslicarbazepine acetate as add-on treatment in patients with focalonset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98-107.Gil-Nagel A., Lopes-Lima J., Almeida L. et al. Efficacy and safety of 800 and 1200mg Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset epilepsy. Acta Neurol Scand. 2009; 120: 281-7.Gil-Nagel A., Lopes-Lima J., Almeida L. et al. Efficacy and safety of 800 and 1200mg Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset epilepsy. Acta Neurol Scand. 2009; 120: 281-7.Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001; 21: 904-19.Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001; 21: 904-19.Guekht A., Gama H., Öztiryaki A.H. et al. Incidence of adverse events in relation to starting dose and titration regimen of Eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures. Epilepsia. 2011; 52 (6): 108.Guekht A., Gama H., Öztiryaki A.H. et al. Incidence of adverse events in relation to starting dose and titration regimen of Eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures. Epilepsia. 2011; 52 (6): 108.Halász P., Cramer J.A., Hodoba D. et al. Long-term efficacy and safety of Eslicarbazepine acetate: results of a 1-year openlabel extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010; 51: 1963-9.Halász P., Cramer J.A., Hodoba D. et al. Long-term efficacy and safety of Eslicarbazepine acetate: results of a 1-year openlabel extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010; 51: 1963-9.Nunes T., Rocha J., Falcão A. et al. Steadystate plasma and cerebrospinal fluid pharmacokinetics and tolerability of Eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013; 54: 108-116.Nunes T., Rocha J., Falcão A. et al. Steadystate plasma and cerebrospinal fluid pharmacokinetics and tolerability of Eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013; 54: 108-116.

The authors declare that there are no conflicts of interest present.